Decavita - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 166,489 | 218,744 | 296,852 | 320,481 | 397,206 | 515,293 | 544,121 | 609,972 |
| Profit before tax | 24,600 | 49,793 | 23,368 | 57,712 | 89,099 | 124,493 | 106,204 | 107,025 |
| Net profit | 23,370 | 47,387 | 22,200 | 49,055 | 75,734 | 105,819 | 90,273 | 89,587 |
| Equity | 75,940 | 113,008 | 123,268 | 166,258 | 215,030 | 303,101 | 387,122 | 484,767 |
| Liabilities | 14,363 | - | - | - | 55,241 | 61,508 | 91,319 | 81,776 |
| Non-current assets | 9,160 | 20,795 | 33,452 | 58,620 | 48,072 | 40,036 | 57,790 | 72,286 |
| Current assets | 81,143 | 132,392 | 120,547 | 148,691 | 222,199 | 324,573 | 420,651 | 494,257 |
| Total assets | 90,303 | 153,187 | 153,999 | 207,311 | 270,271 | 364,609 | 478,441 | 566,543 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 117,454 | 129,439 | 127,380 |
| Social insurance contributions | - | - | - | - | - | - | 14,172 | 13,696 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +17.5% | +31.4% | +35.7% | +8.0% | +23.9% | +29.7% | +5.6% | +12.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 25.9% | 30.9% | 14.4% | 23.7% | 28.0% | 29.0% | 18.9% | 15.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 30.8% | 41.9% | 18.0% | 29.5% | 35.2% | 34.9% | 23.3% | 18.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 14.0% | 21.7% | 7.5% | 15.3% | 19.1% | 20.5% | 16.6% | 14.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 14.8% | 22.8% | 7.9% | 18.0% | 22.4% | 24.2% | 19.5% | 17.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | - | - | - | 0.3 | 0.2 | 0.2 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 83,245 | 109,372 | 148,426 | 160,241 | 198,603 | 213,222 | 128,028 | 159,125 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Decavita - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-23 | 2026-07-26 | 0.17 |
| 2026-05-03 | 2026-05-03 | 0.04 |
| 2026-04-24 | 2026-04-29 | 0.04 |
| 2026-04-20 | 2026-04-23 | 78.47 |
| 2026-01-16 | 2026-01-28 | 11.06 |
| 2025-11-24 | 2025-12-11 | 0.01 |
| 2025-10-23 | 2025-11-10 | 0.36 |
| 2025-09-16 | 2025-09-22 | 0.01 |
| 2025-03-18 | 2025-03-26 | 127.90 |
| 2025-01-22 | 2025-02-12 | 2.83 |
| 2025-01-16 | 2025-01-19 | 1461.19 |
| 2024-12-17 | 2024-12-20 | 1412.70 |
| 2024-12-10 | 2024-12-16 | 0.29 |
| 2024-11-19 | 2024-12-09 | 0.01 |
| 2024-11-18 | 2024-11-18 | 1218.83 |
| 2024-09-17 | 2024-09-19 | 47.59 |
| 2024-08-20 | 2024-08-20 | 82.54 |
| 2024-07-17 | 2024-07-18 | 85.24 |
| 2024-06-18 | 2024-06-24 | 23.00 |
| 2024-04-23 | 2024-05-02 | 1.82 |
| 2024-03-18 | 2024-03-20 | 1012.85 |
| 2024-01-23 | 2024-02-08 | 0.26 |
| 2023-11-23 | 2023-12-11 | 2.87 |
| 2023-09-18 | 2023-10-12 | 1.28 |
| 2023-05-16 | 2023-05-25 | 84.93 |
| 2023-02-17 | 2023-02-27 | 699.72 |
| 2023-02-06 | 2023-02-16 | 0.42 |
| 2023-01-24 | 2023-02-03 | 0.42 |
| 2022-12-16 | 2023-01-03 | 0.81 |
| 2022-11-29 | 2022-12-12 | 0.81 |
| 2022-10-18 | 2022-10-18 | 701.93 |
| 2022-05-17 | 2022-05-19 | 674.48 |
| 2022-02-25 | 2022-03-09 | 0.11 |
| 2022-02-21 | 2022-02-23 | 0.11 |
Decavita - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Decavita is: 2 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-02 | 2.27 |
| 2026-07-02 | 2026-07-07 | 1948.86 |
| 2026-05-26 | 2026-05-26 | 8.82 |
| 2026-04-28 | 2026-05-03 | 0.41 |
| 2026-04-03 | 2026-04-13 | 69.68 |
| 2026-04-02 | 2026-04-02 | 1648.39 |
| 2026-03-08 | 2026-03-08 | 39.37 |
| 2026-03-02 | 2026-03-07 | 39.34 |
| 2026-02-27 | 2026-03-01 | 0.09 |
| 2026-02-21 | 2026-02-26 | 34.64 |
| 2025-12-18 | 2025-12-23 | 0.26 |
| 2025-03-28 | 2025-04-14 | 3.53 |
| 2025-03-06 | 2025-03-06 | 356.81 |
| 2025-02-13 | 2025-02-13 | 123.51 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Decavita, UAB (code 304245797) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €610.0K and net profit of €89.6K, with a profit margin of 14.7%. Revenue increased by 12.1% year on year and by 18.4% over two years, showing steady top-line expansion. At the same time, net profit moved from €105.8K in 2023 to €90.3K in 2024 and €89.6K in 2025, indicating a gradual decline in profitability as turnover grew. The balance sheet remained strong, with total assets of €566.5K, equity of €484.8K and liabilities of €81.8K in 2025. The equity ratio stood at 85.6%, debt-to-equity was 0.17, and asset turnover reached 1.08x. Productivity was solid, with revenue per employee of €203.3K and profit per employee of €29.9K.